FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891966535> ?p ?o ?g. }

• W2891966535 abstract "8049 Background: Complete response in AL is defined as normal FLC ratio with negative serum and urine immunofixation. It is not clear if high involved serum FLC (hIFLC) in a patient with normal ratio may contribute to ongoing amyloid formation and hence affect outcomes. Methods: Data of 1308 patients (pts) with systemic AL seen within 90 days of diagnosis, at Mayo Clinic between 2006-2015, was analyzed retrospectively. Among these, 369 pts had 2 consecutive normal FLC ratio values after 1st line treatment and form the study population. Log rank test was used to estimate survival differences. Results: Among these 369 pts, pts with hIFLC at 1 st reading of normal FLC ratio (hIFLC1; n=170; 46.1%) were compared to those who did not (n=199; 53.9%). At diagnosis, the median age [61.5 vs 60.8 years (y); p=0.2], proportion of males (62.4 vs 58.3%; p=0.4), percentage of pts with renal involvement (73.5 vs 64.8%; p=0.07), in mayo stage I / II / III / IV (32.9% / 23%/ 27.3% / 16.8% vs 43.6 %/ 22.9% / 18.1% / 15.4%; p=0.1), with bone marrow plasma cells >10% (24.2 vs 30%; p=0.2) and with presence of t(11; 14)(48.4 vs 60; p=0.08) was similar, while cardiac (67.5 vs 53.3%; p=0.006) and hepatic (18.2 vs 9.1%; p=0.01) involvement was higher in hIFLC1 group. The median follow-up from diagnosis was 6.1 y (95% CI; 5.6, 6.8). The median progression free survival (PFS) in pts who had hIFLC1 was lower than for those who did not; 2.6 y (95% CI; 1.9, 4.5) vs 5.2 y (95% CI; 4.6, 6.4), p<0.0001, as was the median overall survival [OS; 6.7 y (95% CI; 4.5, 8.3) vs not reached (NR), p<0.0001]. We performed a more stringent comparison for pts with 2 consecutive hIFLC values (hIFLC2; n=112; 30.4%) versus not (n=257; 69.6%). The median PFS (3.2 y; 95%CI; 2.2, 4.5 vs 5.6 y; 95% CI; 4.7, 7.1; p<0.0001) and OS (7.8 y; 95% CI; 6.4, NR vs NR; 95%CI; 9.5, NR; p<0.0001) were significantly reduced in pts with hIFLC2 versus not as well. A multivariate analysis confirmed an impact of hIFLC1 and hIFLC2 on PFS/OS independent of serum creatinine. Conclusions: In pts with systemic AL, persistent elevation of the involved FLC predicts for poor prognosis (independent of serum creatinine) even among those who achieved normal FLC ratio after 1st line treatment." @default.
• W2891966535 created "2018-09-27" @default.
• W2891966535 creator A5001453763 @default.
• W2891966535 creator A5002248011 @default.
• W2891966535 creator A5007747233 @default.
• W2891966535 creator A5012403700 @default.
• W2891966535 creator A5016853434 @default.
• W2891966535 creator A5017390274 @default.
• W2891966535 creator A5023193953 @default.
• W2891966535 creator A5026574827 @default.
• W2891966535 creator A5029802364 @default.
• W2891966535 creator A5033220547 @default.
• W2891966535 creator A5035070160 @default.
• W2891966535 creator A5036150860 @default.
• W2891966535 creator A5037323115 @default.
• W2891966535 creator A5042275995 @default.
• W2891966535 creator A5051470930 @default.
• W2891966535 creator A5066940168 @default.
• W2891966535 creator A5068637846 @default.
• W2891966535 creator A5072502164 @default.
• W2891966535 creator A5076611748 @default.
• W2891966535 creator A5077401586 @default.
• W2891966535 date "2017-05-20" @default.
• W2891966535 modified "2023-09-28" @default.
• W2891966535 title "Outcomes according to involved free light chain (FLC) levels in patients with normal FLC ratio after initial therapy in light chain amyloidosis (AL)." @default.
• W2891966535 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.8049" @default.
• W2891966535 hasPublicationYear "2017" @default.
• W2891966535 type Work @default.
• W2891966535 sameAs 2891966535 @default.
• W2891966535 citedByCount "0" @default.
• W2891966535 crossrefType "journal-article" @default.
• W2891966535 hasAuthorship W2891966535A5001453763 @default.
• W2891966535 hasAuthorship W2891966535A5002248011 @default.
• W2891966535 hasAuthorship W2891966535A5007747233 @default.
• W2891966535 hasAuthorship W2891966535A5012403700 @default.
• W2891966535 hasAuthorship W2891966535A5016853434 @default.
• W2891966535 hasAuthorship W2891966535A5017390274 @default.
• W2891966535 hasAuthorship W2891966535A5023193953 @default.
• W2891966535 hasAuthorship W2891966535A5026574827 @default.
• W2891966535 hasAuthorship W2891966535A5029802364 @default.
• W2891966535 hasAuthorship W2891966535A5033220547 @default.
• W2891966535 hasAuthorship W2891966535A5035070160 @default.
• W2891966535 hasAuthorship W2891966535A5036150860 @default.
• W2891966535 hasAuthorship W2891966535A5037323115 @default.
• W2891966535 hasAuthorship W2891966535A5042275995 @default.
• W2891966535 hasAuthorship W2891966535A5051470930 @default.
• W2891966535 hasAuthorship W2891966535A5066940168 @default.
• W2891966535 hasAuthorship W2891966535A5068637846 @default.
• W2891966535 hasAuthorship W2891966535A5072502164 @default.
• W2891966535 hasAuthorship W2891966535A5076611748 @default.
• W2891966535 hasAuthorship W2891966535A5077401586 @default.
• W2891966535 hasConcept C121332964 @default.
• W2891966535 hasConcept C126322002 @default.
• W2891966535 hasConcept C1276947 @default.
• W2891966535 hasConcept C159654299 @default.
• W2891966535 hasConcept C163864487 @default.
• W2891966535 hasConcept C199185054 @default.
• W2891966535 hasConcept C203014093 @default.
• W2891966535 hasConcept C2778808339 @default.
• W2891966535 hasConcept C2779551797 @default.
• W2891966535 hasConcept C2779951007 @default.
• W2891966535 hasConcept C36394416 @default.
• W2891966535 hasConcept C542903549 @default.
• W2891966535 hasConcept C71924100 @default.
• W2891966535 hasConceptScore W2891966535C121332964 @default.
• W2891966535 hasConceptScore W2891966535C126322002 @default.
• W2891966535 hasConceptScore W2891966535C1276947 @default.
• W2891966535 hasConceptScore W2891966535C159654299 @default.
• W2891966535 hasConceptScore W2891966535C163864487 @default.
• W2891966535 hasConceptScore W2891966535C199185054 @default.
• W2891966535 hasConceptScore W2891966535C203014093 @default.
• W2891966535 hasConceptScore W2891966535C2778808339 @default.
• W2891966535 hasConceptScore W2891966535C2779551797 @default.
• W2891966535 hasConceptScore W2891966535C2779951007 @default.
• W2891966535 hasConceptScore W2891966535C36394416 @default.
• W2891966535 hasConceptScore W2891966535C542903549 @default.
• W2891966535 hasConceptScore W2891966535C71924100 @default.
• W2891966535 hasLocation W28919665351 @default.
• W2891966535 hasOpenAccess W2891966535 @default.
• W2891966535 hasPrimaryLocation W28919665351 @default.
• W2891966535 hasRelatedWork W1991896671 @default.
• W2891966535 hasRelatedWork W1998251393 @default.
• W2891966535 hasRelatedWork W2004280827 @default.
• W2891966535 hasRelatedWork W2009802594 @default.
• W2891966535 hasRelatedWork W2030932774 @default.
• W2891966535 hasRelatedWork W2062726745 @default.
• W2891966535 hasRelatedWork W2090800579 @default.
• W2891966535 hasRelatedWork W2103157431 @default.
• W2891966535 hasRelatedWork W2168397358 @default.
• W2891966535 hasRelatedWork W2173853912 @default.
• W2891966535 hasRelatedWork W2318863492 @default.
• W2891966535 hasRelatedWork W2352942962 @default.
• W2891966535 hasRelatedWork W2469416109 @default.
• W2891966535 hasRelatedWork W2549423107 @default.
• W2891966535 hasRelatedWork W2756107941 @default.
• W2891966535 hasRelatedWork W2793475829 @default.
• W2891966535 hasRelatedWork W3032044795 @default.
• W2891966535 hasRelatedWork W3134321055 @default.
• W2891966535 hasRelatedWork W3157377052 @default.
• W2891966535 hasRelatedWork W3183670199 @default.

• next